Court rejects Celexa patent listing
FDA's "ministerial" role in declining to list certain patents in the "Orange Book" affirmed by a D.C. federal judge Aug. 13. Court rules FDA did not err in refusing Alphapharm's request to list a patent for Forest's antidepressant Celexa and accept its ANDA with a Paragraph IV certification. No patents for Celexa are listed; consequently, no ANDA filers will receive 180-day exclusivity for generic citalopram...
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.